Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Castle Biosciences Inc(CSTL)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CSTL
10/23/2026: CSTL (2-star) is currently NOT-A-BUY. Pass it for now.
Castle Biosciences is a high-growth healthcare company focused on providing specialized diagnostic and prognostic tests for skin and gastrointestinal cancers. The company has a leading position in dermatology diagnostics and has successfully broadened its reach into gastroenterology, demonstrating strong revenue scaling. Its primary investment story hinges on increasing physician adoption of its proprietary gene expression tests. However, the company faces risks related to payer reimbursement policies, intense laboratory competition, and the challenge of sustaining growth while managing costs. This stock may suit growth investors willing to tolerate volatility, who should monitor updates on clinical evidence and insurance coverage developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company exhibits high top-line growth potential within the specialized diagnostics market. |
| Momentum investor | Mixed fit | Momentum appeal depends on the consistent achievement of growth milestones and positive stock price trends. |
| Value investor | Weak fit | The company's current valuation reflects high growth expectations rather than established earnings-based value. |
| Dividend investor | Weak fit | Castle Biosciences does not pay a dividend and prioritizes capital reinvestment. |
| Low-risk investor | Weak fit | Small-cap diagnostic companies often experience higher volatility and regulatory risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | As a growth-stage diagnostic company, share price swings are common based on clinical or reimbursement news. |
| Valuation risk | Medium / high | Market expectations for future growth may lead to premium pricing that is sensitive to growth misses. |
| Competition risk (Diagnostic Lab competition) | Medium | The company faces established competitors with greater resources for test development and commercialization. |
| Business quality | Medium | The company has strong, proprietary products but is still maturing in terms of diversified revenue streams. |
| Dividend income | Low / none | No dividends are paid, making the stock unsuitable for income-focused portfolios. |
| Execution risk | Medium | Growth requires successful, ongoing execution of sales strategies and securing payer reimbursement for new tests. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 9.04% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.01B USD | Price to earnings Ratio - | 1Y Target Price 45.22 |
Price to earnings Ratio - | 1Y Target Price 45.22 | ||
Volume (30-day avg) 366.9K shares | Beta 0.94 | 52 Weeks Range 17.72 - 44.28 | Updated Date 10/25/2026 |
52 Weeks Range 17.72 - 44.28 | Updated Date 10/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.64 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Dermatology Diagnostics | DecisionDx-Melanoma, DecisionDx-SCC, and other skin cancer tests. | Revenue comes from physicians ordering these tests for patients to help decide the best treatment path. |
| Gastroenterology Diagnostics | TissueCypher and related Barrett's esophagus testing. | This is a newer, high-growth area where the company provides data to help manage digestive health conditions. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 406.28M | Price to Sales(TTM) 2.83 |
Enterprise Value 406.28M | Price to Sales(TTM) 2.83 | ||
Enterprise Value to Revenue 1.17 | Enterprise Value to EBITDA 42.95 | Shares Outstanding 30.55M | Shares Floating 27.18M |
Shares Outstanding 30.55M | Shares Floating 27.18M | ||
Percent Insiders 2.36 | Percent Institutions 91.04 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.